Contrary to your anticapitalist sentiments, Calico’s science is headed up by Cynthia Kenyon, who is hellbent on creating anti-aging interventions for her own sake as well as for the sake of everyone else. Kenyon is one of the very top scientists in the world with the kind of insight and resources to make aging interventions a practical and widespread reality. Her concepts are worlds ahead of the antiquated SENS ideas and far more likely to bear fruit in the nearer term. Buck has nothing, so no reason to bring them up by comparison.
Stay tuned. I think it’s a race between the brilliance of Cynthia and the brilliance of George Church. If he’s lucky, Craig Venter might have an input as well.
Buck, no. SENS RF, no. The public sector, no. The race is on.
On Thursday, October 23, 2014 2:57 PM, Florin Clapa wrote:
Alex, I’m not sure
that simply repairing damage can be equated with helping SENS in
this case. Statins also repair damage to a certain extent (by
shrinking atherosclerotic lesions), but don’t qualify as SENS,
because they mess with metabolism. I suspect your reference to
“the signalome level” might belong in the same category. A quote
at FightAging! about activating endogenous, damage-repair
mechanisms can be interpreted to mean that you’re trying to
upregulate metabolic pathways to increase rates of repair. This
is also MWM from the SENS perspective, but perhaps, you meant
something else. Can you clarify this issue?
On 10/23/2014 1:12 PM, Alexander Zhavoronkov wrote:
Medicine’s technology is applicable to several of the
SENS strands because some of our approaches are
essentially looking for ways to repair damage on the
signalome level. We just want to validate the technology
in age-related diseases to develop a more solid revenue
stream. And yes, after we close our second round of
funding we will put a dedicated resource to apply our
technology to three of the SENS strands where we can
help evaluate the possible effectiveness of and screen
for interventions. So SENS makes sense even when you try
to think about it through the prism of Big Data
On Tue, Oct 21, 2014 at 2:21 PM,
The article you linked to has
quotes that could be interpreted as being pro-SENS.
At any rate, Calico may pursue both SENS and
non-SENS approaches. Even some (e.g., InSilico
Medicine) that are sympathetic to SENS are pursuing
non-SENS aging research, because they think it will
lead to the faster development of therapies. Calico
may also share this reasoning to a certain extent.
Since they’re a commercial organization, they might
not want to reveal their strategy too clearly.
On 10/19/2014 5:13 PM, Elliot
A top executive at Google’s antiaging biotechnology company said this week that scientists must identify and understand the underlying biology of age-related diseases like Alzheimer’s before finding a cure.
Barron said researchers must focus on the cellular and molecular mechanisms of a disease before developing possible treatments
“it behooves us to really spend a lot of time trying to understand the biology of human disease,” said the clinician-scientist
Does anyone know if they have, somewhere, any actual arguments against the things Aubrey de Grey has explained? E.g. that you don’t have to understand all the biological details “before” you can do anything about aging . Or are they just kinda ignoring the arguments in the field and proceeding irrationally?
I checked their website for arguments, but they’ve chosen not to put up any ideas about why their approach is right or how to think about the field. Nor do they link to an explanation by someone else they think is good and are using. So how is one supposed to criticize any methodological mistakes they may be making, or judge whether they are doing a good job, etc?
 de Grey, Aubrey; Rae, Michael (2007-09-04). Ending Aging: The Rejuvenation Breakthroughs That Could Reverse Human Aging in Our Lifetime (pp. 5-6). St. Martin’s Press. Kindle Edition.
For decades, my colleagues and I had been earnestly investigating aging in the same way that historians might “investigate” World War I: as an almost hopelessly complex historical tragedy about which everyone could theorize and argue, but about which nothing could fundamentally be done. Perhaps inhibited by the deeply ingrained belief that aging was “natural” and “inevitable,” biogerontologists had set themselves apart from the rest of the biomedical community by allowing themselves to be overawed by the complexity of the phenomenon that they were observing.
That night, I swept aside all that complexity, revealing a new simplicity in a complete redefinition of the problem. To intervene in aging, I realized, didn’t require a complete understanding of all the myriad interacting processes that contribute to aging damage. To design therapies , all you have to understand is aging damage itself: the molecular and cellular lesions that impair the structure and function of the body’s tissues. Once I realized that simple truth, it became clear that we are far closer to real solutions to treating aging as a biomedical problem, amenable to therapy and healing, than it might otherwise seem.
(More detailed explanation can be found in the book.)